Kimberly-Clark Corporation

Kimberly-Clark Corporation (KMB) Market Cap

Kimberly-Clark Corporation has a market capitalization of .

No quote data available.

CEO: Michael D. Hsu

Sector: Consumer Defensive

Industry: Household & Personal Products

IPO Date: 1980-03-17

Website: https://www.kimberly-clark.com

Kimberly-Clark Corporation (KMB) - Company Information

Market Cap: -|Sector: Consumer Defensive

Company Profile

Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products worldwide. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The Personal Care segment offers disposable diapers, swimpants, training and youth pants, baby wipes, feminine and incontinence care products, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Depend, Plenitud, Softex, Poise, and other brand names. The Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The K-C Professional segment offers wipers, tissues, towels, apparel, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. The company sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to manufacturing, lodging, office building, food service, and public facilities, as well as through distributors and e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.

Analyst Sentiment

64%
Buy

From 16 Active Polls

1Y Forecast: $101.67

▲ +0.0% Potential Upside

Consensus Target Metrics

Low Bound

$99

Median

$100

High Bound

$106

Average

$102

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$101.67
▲ +2.66% Upside
Low Target
$99.00
-0% Risk
Median Target
$100.00
1% Mid
High Target
$106.00
7% Max

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

Sentiment volume allocation data unavailable.

Historical valuation matrix unavailable.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 KIMBERLY CLARK CORP (KMB) — Investment Overview

🧩 Business Model Overview

Kimberly-Clark produces and sells high-frequency hygiene products that consumers repurchase on a regular cadence: facial tissue, toilet/tissue formats, diapers/training pants, adult care items, and baby/wipes and related offerings. The value chain blends (1) procurement of paper and absorbent inputs, (2) converting/manufacturing into engineered consumer formats, (3) packaging and logistics, and (4) distribution through retail partners and away-from-home channels.

The model benefits from scale-based manufacturing efficiency and established brand placement, which supports shelf availability and retailer relationships—creating practical “household shelf stickiness” even though individual SKUs are not contractually locked in.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by repeat, transactional demand rather than contract-based recurring revenue. Monetisation relies on maintaining volume and defending unit economics through:

  • Mix and tiering: premium absorbency, convenience packs, and category-leading formats typically support better pricing and lower relative promotional intensity.
  • Cost pass-through: the ability to offset input inflation (pulp/fiber, chemicals, energy) through pricing actions and product mix.
  • Channel leverage: maintaining retailer participation and optimizing logistics costs improves realized margins.
  • Operating leverage: fixed-cost absorption in converting plants and disciplined manufacturing utilization can expand margins when demand stabilizes.

Operating margin outcomes are most sensitive to commodity costs, freight/energy, FX translation, and competitive promotion intensity.

🧠 Competitive Advantages & Market Positioning

Kimberly-Clark’s moat is best characterized as Scale/Distribution leverage combined with Private-label resistance driven by product performance and brand-led innovation. While consumer goods face frequent promotions, competitors generally must match performance and manufacturing efficiency to sustain share gains.

  • Scale in converting and procurement: larger input volumes and established supplier relationships support more favorable economics and steadier supply—improving the ability to navigate commodity cycles.
  • Private-label resistance: in tissue and personal care categories, consumers often trade down only when price pressure becomes extreme. Performance-linked features (absorbency, softness, fit, leakage protection) raise the burden for private labels to win meaningful displacement.
  • Retail and channel execution: broad distribution relationships help protect shelf share and enable faster coordinated responses to cost and demand swings.

Competitive benchmarking (examples):

  • Procter & Gamble (P&G): heavier emphasis on diapers and grooming-adjacent formats with strong consumer reach; P&G competes for premium diaper and family care occasions, often relying on household distribution strength.
  • Essity: significant footprint in hygiene and health categories (tissue and institutional/professional hygiene). Essity competes more directly in hygiene solutions and away-from-home channels, where spec and contract wins matter.
  • Unicharm: strong in baby and hygiene products, particularly with premiumization strategies in Asia. Unicharm’s advantage often centers on localized innovation and regional market penetration.

Compared with these rivals, Kimberly-Clark’s industry focus emphasizes a broad, global portfolio spanning tissue and personal care—supporting cross-category bargaining power with suppliers and retailers, and enabling continued investment in converting capabilities and product engineering to defend performance tiers.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is more likely to come from category expansion and share/quality mix than from new revenue streams:

  • Premiumization in hygiene: higher-absorbency and convenience formats typically offer better economics than value-only offerings, supporting margin durability as households prefer improved performance per use.
  • Demographics and household formation: baby and childcare categories benefit from population dynamics and urbanization trends, while adult care demand can rise with aging demographics.
  • Professional hygiene (away-from-home): durable demand drivers from workplace, healthcare, hospitality, and sanitation spending can support steadier reorder cycles than pure consumer channels.
  • Operational efficiency and product engineering: continuous improvement in yield, converting efficiency, and formulation can reduce unit costs and protect margins even when inputs fluctuate.
  • Emerging market penetration: adoption of branded hygiene solutions typically expands as distribution improves and consumer purchasing power rises, broadening TAM versus mature markets.

⚠ Risk Factors to Monitor

  • Commodity and input volatility: pulp/fiber, energy, chemicals, and transportation costs can compress margins without sufficient pricing and mix offsets.
  • Competitive promotion and private-label pressure: retailer-driven pricing actions can increase unit sales but may reduce profitability if promotional intensity rises.
  • FX and regional demand shifts: currency movements and uneven category growth across geographies can affect reported results and cash generation.
  • Regulatory and environmental constraints: packaging, emissions, water stewardship, and sustainable sourcing requirements can raise compliance costs or require capex.
  • Capital allocation and restructuring execution: manufacturing footprint changes, productivity projects, or portfolio actions can affect cost structure during transition periods.

📊 Valuation & Market View

Equity valuation for mature consumer staples generally reflects defensive cash flow characteristics and earnings resilience rather than high-growth expectations. Markets often look through short-cycle earnings swings to assess:

  • Free cash flow conversion and sustainability through commodity cycles
  • Operating margin durability (pricing power vs. promotional intensity)
  • Cost discipline and productivity trajectory
  • Capital returns (dividends and buybacks) consistent with leverage targets

Multiple frameworks commonly used in this sector include EV/EBITDA and earnings-based valuation, with P/S used less frequently due to margin sensitivity. Key “needle movers” typically include input cost trends, gross margin/mix performance, and evidence that pricing can remain ahead of cost without excessive volume loss.

🔍 Investment Takeaway

Kimberly-Clark is positioned as a global leader in hygiene and tissue through a combination of scale-enabled cost structure and private-label resistance rooted in product performance, converting capability, and retailer execution. The investment case rests on the company’s ability to defend share and mix while managing input volatility—supporting a durable earnings/cash-flow profile suited to long-term, valuation-disciplined portfolios.


⚠ AI-generated — informational only. Validate using filings before investing.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"KMB (Q1’26, ended 2026-03-31) reported Revenue of $4.163B and Net Income of $521M (EPS: $2). YoY, revenue declined (from $4.840B in Q1’25 to $4.163B), while net income also fell (from $567M to $521M). Specifically, Revenue decreased by ~-14.0% YoY, and Net Income decreased by ~-8.1% YoY. QoQ, revenue was ~+2.0% higher versus $4.080B in Q4’25, while net income rose ~+4.4% versus $499M in Q4’25. Profitability was mixed: gross margin improved modestly over the 4-quarter run (Q1’26 gross margin 36.8% vs ~35.9% in Q4’25), but operating and net profit dynamics softened versus earlier in FY25 (net margin Q1’26: 12.5% vs 11.7% in Q1’25). Cash flow remained solid. Operating cash flow was $745M in Q1’26, and free cash flow was $321M after $424M of capex; dividends remain large and stable with dividends paid of $418M (a payout ratio ~80% in the quarter). Shareholder returns likely remain pressured given the weak market trend (1y price change -29.3%) despite a modest dividend yield (~1.3%); buybacks appear minimal in this dataset. Overall, results show resilient cash generation but weaker top-line/earnings than last year, with leverage elevated (debt-to-equity remains very high)."

Revenue Growth

Caution

Revenue was $4.163B in Q1’26, down ~-14.0% YoY (vs $4.840B in Q1’25) but up ~+2.0% QoQ (vs $4.080B in Q4’25).

Profitability

Fair

Net income was $521M, down ~-8.1% YoY, but up ~+4.4% QoQ. Net margin ticked to 12.5% in Q1’26 (vs 12.2% in Q4’25), with gross margin improving to 36.8%.

Cash Flow Quality

Neutral

Operating cash flow was strong at $745M and free cash flow was $321M. Dividends of $418M were steady with an ~80% payout ratio in Q1’26; buybacks were not evident in this quarter’s cash flow.

Leverage & Balance Sheet

Neutral

Total assets were ~${17.18B} with elevated leverage: long-term debt ~6.48B and debt-to-equity remains very high (debtEquityRatio 3.61 in Q1’26 per ratios). Equity is thin, limiting resilience.

Shareholder Returns

Neutral

Price momentum is negative: 1y_change -29.25% and 6m_change -17.43%. Dividend yield is modest (~1.3%), so total return is likely dominated by capital depreciation.

Analyst Sentiment & Valuation

Fair

Consensus price target is ~$110.67 vs current ~$98.84 (implied upside ~12%). Valuation multiples appear elevated (e.g., P/E ~15.4), consistent with a defensive brand but not cheap on earnings.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

KMB reported Q1 momentum driven by innovation and a disciplined revenue-growth model: volume + mix rose to 3%, supported by science-backed execution across Baby Care, Women’s Health, and active aging. The main financial overhang in the quarter-forward view is the combination of Middle East-related inflation and a California DC fire. Management quantified Q2 impacts at ~$20M top-line (70–80 bps North America segment headwind) and ~$50M bottom-line, with LA recovery expected in 2H. Looking further, they flagged back-half incremental gross input costs of ~$150M–$170M if oil averages ~$100/bbl, explicitly noting mitigations are still being worked and not fully embedded into outlook. Offsetting confidence rests on integrated margin management (pricing net of costs discipline), a rich productivity pipeline, and already-strong execution (6% gross productivity with Q1 operating profit margin up ~20 bps). With margin expansion targeted ~70–80 bps for the year, the tone is cautious: costs are still a moving target, but tools and historical recovery capability are emphasized.

AI IconGrowth Catalysts

  • Powering Care innovation driving 3% volume + mix growth in Q1 (sustaining multi-quarter broad-based volume+mix growth)
  • Second-quarter late launch that is described as one of the most active ever across Baby Care, Women’s Health, and active aging
  • Diapers innovation/trial driving promotional effectiveness (Snug & Dry; new absorbent core) with reported post-promo household penetration/velocities up

Business Development

  • Kenvue integration planning: management team reflects ~50/50 bench from Kenvue and Kimberly-Clark; creation of 40+ integration teams for post-close planning
  • Supplier relationship actions: sit-downs, renegotiating contracts where force majeure/surcharges are enacted, and hedging/programmatic elements referenced within integrated margin management

AI IconFinancial Highlights

  • Input cost inflation framing: ~$200M input cost inflation faced in 2024-2025; January 2026 outlook was flat; latest data introduces additional pressure not yet fully built into guidance
  • Q2 top-line impact: ~$20M from California DC fire, translating to ~70–80 bps headwind for North America in Q2
  • Q2 bottom-line impact: ~$50M from Middle East war inflation impacts and additional impacts related to LA DC fire (with expected recovery in 2H)
  • Back-half additional gross incremental input costs under oil ~ $100/bbl avg: ~$150M–$170M (not built into outlook; mitigations also not built in yet)
  • Productivity: delivered 6% gross productivity in Q1; plan to deliver 6% for full year
  • Operating profit margin: expanded in Q1 by ~20 bps; also cited ~90 bps year-over-year overhead improvement (overhead down to 13%)
  • Gross margin: Q1 gross margin sequentially expanded vs Q4; gross margin vs prior year slightly down ~60 bps attributed to last full quarter of impact from exit of North America private label contract
  • Full-year margin outlook: gross margin and operating profit margin expected to expand in the vicinity of ~70–80 bps

AI IconCapital Funding

    AI IconStrategy & Ops

    • Fast lean operating model for agility amid turbulence
    • PNOC discipline reiterated: pricing net of commodity/cost inputs expected to be neutral over time via integrated margin management
    • North America promotional posture: weighted average promo intensity down vs pre-COVID and category levels; promo used to drive trial tied to innovation agenda
    • Channel execution shift: reallocation of investments across channels including surgical programming to ensure Huggies buyers can find the brand after recent distribution change (club channel); normalization expected through 2026
    • Supply chain investment: $2B announced previously (progressing as planned)

    AI IconMarket Outlook

    • Global category growth outlook updated to 2.5% (from 2% previously); trailing 12-month weighted average category growth ~2.5% and management expects it to remain similar
    • North America category growth cited around 3.3% in commentary; management indicated uncertainty but believes recent rebound is a one-off after cycling Q4/lag dynamics
    • Q2 organic sales growth: expected slightly below Q1 due to strongest comp cycle (total enterprise ~4% last year; North America volume ~5%) and the $20M California DC fire headwind

    AI IconRisks & Headwinds

    • Oil price risk: if oil remains ~ $100/bbl on average, management cites potential incremental gross input costs of ~$150M–$170M in the back half (mitigations not yet built into outlook)
    • Geographic disruption: California DC fire (Q2 ~$20M top-line impact; ~70–80 bps North America headwind) and related recovery expected in 2H
    • Middle East war-related inflation impacts driving Q2 ~$50M bottom-line headwind
    • Turbulent operating environment with competitive promotion and uncertainty around category timing/comps

    Q&A: Analyst Interest

    • Oil/input-cost and scenario planning: Management outlined that back-half gross incremental input costs could be ~$150M–$170M if oil averages ~$100/bbl, and that mitigations (pricing, hedging, supplier actions, and productivity) are not fully built into the outlook yet due to moving costs and scenarios.
    • North America pricing & promotions discipline: Management emphasized PNOC (pricing net of costs) neutrality over time, with North America weighted promo intensity down vs pre-COVID, and promotion used specifically to drive trial for innovation (e.g., Snug & Dry). They described normalization through 2026 after distribution-driven channel investment shifts.
    • Kenvue merger/integration status and org structure: Management described a market-centric but globally scaled operating model, with integration planning via 40+ teams and a ~50/50 leadership bench. They characterized Kenvue’s recent issues as executional (not structural), cited their operating-model change in February, and focused on line-of-sight synergies in COGS and SG&A.

    Sentiment: CAUTIOUS

    Note: This summary was synthesized by AI from the KMB Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

    Loading financial data and tables...
    © 2026 Stock Market Info — Kimberly-Clark Corporation (KMB) Financial Profile